Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $106M | $-81M | $-81M | $-35M | -30.2% | 38.9% | -33.9% |
| 2024 | $76M | $-109M | $-123M | $-113M | -36.2% | 0.4% | 3.4% |
| 2023 | $76M | $-121M | $-119M | $-122M | -25.5% | -81.6% | -195.4% |
| 2022 | $412M | $142M | $124M | $131M | 25.2% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 105.96 |
| Operating Revenue | 105.96 |
| Operating Expense | 198.50 |
| Research And Development | 137 |
| Selling General And Administration | 61.50 |
| Total Expenses | 198.50 |
| Operating Income | -92.54 |
| Total Operating Income As Reported | -92.55 |
| EBITDA | -81.42 |
| Normalized EBITDA | -80.82 |
| EBIT | -92.54 |
| Interest Income | 13.35 |
| Net Interest Income | 13.35 |
| Other Non Operating Income Expenses | 0.05 |
| Other Income Expense | -0.56 |
| Interest Income Non Operating | 13.35 |
| Net Non Operating Interest Income Expense | 13.35 |
| Pretax Income | -79.75 |
| Tax Provision | 1.38 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -0.13 |
| Net Income Continuous Operations | -81.13 |
| Net Income From Continuing And Discontinued Operation | -81.13 |
| Net Income From Continuing Operation Net Minority Interest | -81.13 |
| Net Income | -81.13 |
| Net Income Common Stockholders | -81.13 |
| Net Income Including Noncontrolling Interests | -81.13 |
| Normalized Income | -80.65 |
| Diluted NI Availto Com Stockholders | -81.33 |
| Basic Average Shares | 75.40 |
| Diluted Average Shares | 75.41 |
| Reconciled Depreciation | 11.11 |
| Total Unusual Items | -0.61 |
| Total Unusual Items Excluding Goodwill | -0.61 |
| Special Income Charges | 0 |
| Impairment Of Capital Assets | 0 |
| Gain On Sale Of Security | -0.61 |
| General And Administrative Expense | 61.50 |
| Other Gand A | 30.60 |
| Salaries And Wages | 30.90 |
| Otherunder Preferred Stock Dividend | - |
| Average Dilution Earnings | -0.20 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Zymeworks Inc.this co. | ZYME | $1.8B | -22.76 | 6.88 | -30.2% | -22.40 |
| Astrana Health, Inc. | ASTH | $1.9B | 83.46 | 2.41 | 2.9% | 18.67 |
| Stoke Therapeutics, Inc. | STOK | $1.9B | -272.47 | 5.32 | -2.0% | -95.36 |
| Pulse Biosciences, Inc. | PLSE | $1.9B | -25.62 | 23.12 | -90.2% | -23.61 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B |
| - |
| - |
| - |
| - |
| - |
| -14.08 |
| 8.67 |
| -61.6% |
| -13.48 |
| Pediatrix Medical Group, Inc. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Vericel Corporation | VCEL | $1.8B | 110.33 | 5.14 | 4.7% | 60.29 |
| ANI Pharmaceuticals, Inc. | ANIP | $1.8B | 22.99 | 3.33 | 14.5% | 10.29 |
| Peer Median | - | 2.88 | 4.23 | 0.5% | 1.35 | |